309 related articles for article (PubMed ID: 32773089)
1. Labeling a TCO-functionalized single domain antibody fragment with
Zhou Z; Zalutsky MR; Vaidyanathan G
Bioorg Med Chem; 2020 Sep; 28(17):115634. PubMed ID: 32773089
[TBL] [Abstract][Full Text] [Related]
2. An Efficient Method for Labeling Single Domain Antibody Fragments with
Zhou Z; Devoogdt N; Zalutsky MR; Vaidyanathan G
Bioconjug Chem; 2018 Dec; 29(12):4090-4103. PubMed ID: 30384599
[TBL] [Abstract][Full Text] [Related]
3. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G
Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937
[TBL] [Abstract][Full Text] [Related]
4. Site-Specific and Residualizing Linker for
Zhou Z; Meshaw R; Zalutsky MR; Vaidyanathan G
J Nucl Med; 2021 Nov; 62(11):1624-1630. PubMed ID: 33637584
[TBL] [Abstract][Full Text] [Related]
5. Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.
Feng Y; Zhou Z; McDougald D; Meshaw RL; Vaidyanathan G; Zalutsky MR
Nucl Med Biol; 2021 Jan; 92():171-183. PubMed ID: 32448731
[TBL] [Abstract][Full Text] [Related]
6. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[
Zhou Z; McDougald D; Devoogdt N; Zalutsky MR; Vaidyanathan G
Mol Pharm; 2019 Jan; 16(1):214-226. PubMed ID: 30427188
[TBL] [Abstract][Full Text] [Related]
7. Labeling single domain antibody fragments with
Zhou Z; McDougald D; Meshaw R; Balyasnikova I; Zalutsky MR; Vaidyanathan G
Nucl Med Biol; 2021; 100-101():24-35. PubMed ID: 34146837
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.
Vaidyanathan G; McDougald D; Choi J; Koumarianou E; Weitzel D; Osada T; Lyerly HK; Zalutsky MR
J Nucl Med; 2016 Jun; 57(6):967-73. PubMed ID: 26912425
[TBL] [Abstract][Full Text] [Related]
9. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
Zhou Z; Vaidyanathan G; McDougald D; Kang CM; Balyasnikova I; Devoogdt N; Ta AN; McNaughton BR; Zalutsky MR
Mol Imaging Biol; 2017 Dec; 19(6):867-877. PubMed ID: 28409338
[TBL] [Abstract][Full Text] [Related]
10. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.
Choi J; Vaidyanathan G; Koumarianou E; Kang CM; Zalutsky MR
Nucl Med Biol; 2018 Jan; 56():10-20. PubMed ID: 29031230
[TBL] [Abstract][Full Text] [Related]
11. Improved stability of a novel fluorine-18 labeled TCO analogue for pretargeted PET imaging.
Ruivo E; Adhikari K; Elvas F; Fissers J; Vangestel C; Staelens S; Stroobants S; Van der Veken P; Wyffels L; Augustyns K
Nucl Med Biol; 2019; 76-77():36-42. PubMed ID: 31707309
[TBL] [Abstract][Full Text] [Related]
12. (18)F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry.
Meyer JP; Houghton JL; Kozlowski P; Abdel-Atti D; Reiner T; Pillarsetty NV; Scholz WW; Zeglis BM; Lewis JS
Bioconjug Chem; 2016 Feb; 27(2):298-301. PubMed ID: 26479967
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Organo [
Otaru S; Imlimthan S; Sarparanta M; Helariutta K; Wähälä K; Airaksinen AJ
Molecules; 2020 Mar; 25(5):. PubMed ID: 32156020
[TBL] [Abstract][Full Text] [Related]
14. Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose
Feng Y; Meshaw R; Zhao XG; Jannetti S; Vaidyanathan G; Zalutsky MR
J Nucl Med; 2023 Jan; 64(1):124-130. PubMed ID: 35618478
[TBL] [Abstract][Full Text] [Related]
15. Trans-cyclooctene tag with improved properties for tumor pretargeting with the diels-alder reaction.
Rossin R; van Duijnhoven SM; Läppchen T; van den Bosch SM; Robillard MS
Mol Pharm; 2014 Sep; 11(9):3090-6. PubMed ID: 25077373
[TBL] [Abstract][Full Text] [Related]
16. Pretargeted PET Imaging Using a Bioorthogonal
Billaud EMF; Belderbos S; Cleeren F; Maes W; Van de Wouwer M; Koole M; Verbruggen A; Himmelreich U; Geukens N; Bormans G
Bioconjug Chem; 2017 Dec; 28(12):2915-2920. PubMed ID: 29191024
[TBL] [Abstract][Full Text] [Related]
17. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.
Vaidyanathan G; Jestin E; Olafsen T; Wu AM; Zalutsky MR
Nucl Med Biol; 2009 Aug; 36(6):671-80. PubMed ID: 19647173
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of an
Feng Y; Meshaw R; McDougald D; Zhou Z; Zhao XG; Jannetti SA; Reiman RE; Pippen E; Marjoram R; Schaal JL; Vaidyanathan G; Zalutsky MR
Sci Rep; 2022 Feb; 12(1):3020. PubMed ID: 35194100
[TBL] [Abstract][Full Text] [Related]
20. Improved metabolic stability for 18F PET probes rapidly constructed via tetrazine trans-cyclooctene ligation.
Selvaraj R; Giglio B; Liu S; Wang H; Wang M; Yuan H; Chintala SR; Yap LP; Conti PS; Fox JM; Li Z
Bioconjug Chem; 2015 Mar; 26(3):435-42. PubMed ID: 25679331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
